Literature DB >> 17192037

Early detection markers in Pancreas Cancer.

James J Farrell1, Marius van Rijnsoever, Hany Elsaleh.   

Abstract

The role of early detection in cancer has shown improved survival for certain cancers, including colon cancer, cervical cancer and breast cancer. The possibility for early detection of pancreatic cancer may be realized by an improved understanding of the histology and molecular genetics of precursor lesions and cancerous lesions in pancreatic cancer and the development of sensitive and specific screening tests (both invasive and non-invasive) to detect early pancreatic cancer. The NIH-NCI Early Detection Research Network (EDRN) in Pancreatic Cancer has been focussed on the development and validation of new biomarkers for the detection of early pancreatic cancer. This review will focus on our understanding of the histologic and molecular model of pancreatic carcinogenesis, current strategies and limitations of screening for pancreatic cancer and the development and validation of new biomarkers for the early detection of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17192037     DOI: 10.3233/cbm-2005-12-304

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

2.  Imaging targeted-agent binding in vivo with two probes.

Authors:  Brian W Pogue; Kimberley S Samkoe; Shannon Hextrum; Julia A O'Hara; Michael Jermyn; Subhadra Srinivasan; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2010 May-Jun       Impact factor: 3.170

3.  Combined small and large magnetic nanoparticle extraction and concentration from biofluids for non-toxic detection of biomarkers.

Authors:  Anatoliy S Lapchuk; Ivan V Gorbov; Alexander V Prygun; Iryna V Balagura; Yevhenii M Morozov
Journal:  Sens Diagn       Date:  2022-06-09

4.  Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer.

Authors:  Lei Zhang; James J Farrell; Hui Zhou; David Elashoff; David Akin; No-Hee Park; David Chia; David T Wong
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

5.  Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma.

Authors:  Shaiju K Vareed; Vadiraja B Bhat; Christopher Thompson; Vihas T Vasu; Damian Fermin; Hyungwon Choi; Chad J Creighton; Sitaram Gayatri; Ling Lan; Nagireddy Putluri; Gagan Singh Thangjam; Punit Kaur; Mohsen Shabahang; Judith G Giri; Alexey I Nesvizhskii; Alexander A A Asea; Anil G Cashikar; Arundhati Rao; James McLoughlin; Arun Sreekumar
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

6.  NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer.

Authors:  Michelle J Schmahl; Daniel P Regan; Adam C Rivers; William C Joesten; Michael A Kennedy
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.